CLINICAL TRIALS PROFILE FOR VELCADE

505(b)(2) Clinical Trials for VELCADE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00116961 ↗	Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma	Completed	University of Michigan Cancer Center	Phase 2	2005-06-01	This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher complete response rates than current treatment options. One of the new medications in multiple myeloma is Velcade. Preliminary results from a study using a combination of Velcade with Doxil have shown high response rates (disease reduction). Preliminary results also show that an addition of dexamethasone to Velcade in patients not responding to Velcade alone showed improved response rates. This study involves treatment with a new combination of three standard medications: Velcade, Doxil, and dexamethasone (VDd combination). The proposed combination of all three drugs may improve efficacy and response. Velcade is approved by the Food and Drug Administration (FDA) for treatment in multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. Velcade is still currently under investigation for other indications. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is a standard therapy for multiple myeloma, but is not approved by the FDA for that use. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with Velcade, Doxil and dexamethasone is an effective treatment and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT00116961 ↗	Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma	Completed	University of Michigan Rogel Cancer Center	Phase 2	2005-06-01	This is a research study for patients with newly diagnosed multiple myeloma. Multiple myeloma remains a non-curable disease however, newer medications and their combinations appear to provide higher response rates and higher complete response rates than current treatment options. One of the new medications in multiple myeloma is Velcade. Preliminary results from a study using a combination of Velcade with Doxil have shown high response rates (disease reduction). Preliminary results also show that an addition of dexamethasone to Velcade in patients not responding to Velcade alone showed improved response rates. This study involves treatment with a new combination of three standard medications: Velcade, Doxil, and dexamethasone (VDd combination). The proposed combination of all three drugs may improve efficacy and response. Velcade is approved by the Food and Drug Administration (FDA) for treatment in multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. Velcade is still currently under investigation for other indications. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is a standard therapy for multiple myeloma, but is not approved by the FDA for that use. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with Velcade, Doxil and dexamethasone is an effective treatment and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT00135187 ↗	Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma	Completed	University of Michigan Cancer Center	N/A	2004-07-01	Patients are being asked to take part in this research study because they have multiple myeloma which has relapsed after (come back), or is refractory to (unaffected by), initial therapy. For patients who have relapsed or are refractory to therapy, there is no agreed upon standard treatment. Treatment options include chemotherapy and, for some patients, bone marrow transplants. None of the available treatments are curative and investigators are continually looking for more effective treatments. This study involves treatment with a new combination of standard drugs: VELCADE, Doxil, and Dexamethasone. Preliminary results from a study using a combination of VELCADE with Doxil showed high response rates (disease reduction). Two other studies showed that an addition of Dexamethasone to VELCADE in patients not responding to VELCADE alone improved response rate. The proposed combination of all three drugs may improve efficacy and response. VELCADE is approved by the Food and Drug Administration (FDA) for use in multiple myeloma. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is approved for use in multiple myeloma. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with VELCADE, Doxil and Dexamethasone is an effective treatment, and also to determine the side effects that occur when this combination treatment is given.
New Combination	NCT00135187 ↗	Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma	Completed	University of Michigan Rogel Cancer Center	N/A	2004-07-01	Patients are being asked to take part in this research study because they have multiple myeloma which has relapsed after (come back), or is refractory to (unaffected by), initial therapy. For patients who have relapsed or are refractory to therapy, there is no agreed upon standard treatment. Treatment options include chemotherapy and, for some patients, bone marrow transplants. None of the available treatments are curative and investigators are continually looking for more effective treatments. This study involves treatment with a new combination of standard drugs: VELCADE, Doxil, and Dexamethasone. Preliminary results from a study using a combination of VELCADE with Doxil showed high response rates (disease reduction). Two other studies showed that an addition of Dexamethasone to VELCADE in patients not responding to VELCADE alone improved response rate. The proposed combination of all three drugs may improve efficacy and response. VELCADE is approved by the Food and Drug Administration (FDA) for use in multiple myeloma. Doxil is not approved for use in multiple myeloma but is an approved drug for use in patients with some other cancers. Several published clinical trials provide evidence that Doxil is an active agent in multiple myeloma and it is used in treatment combinations for multiple myeloma in general practice. Dexamethasone is approved for use in multiple myeloma. The combination of all three drugs is experimental (not FDA approved). The goals of this study are to determine if this new combination therapy with VELCADE, Doxil and Dexamethasone is an effective treatment, and also to determine the side effects that occur when this combination treatment is given.

All Clinical Trials for VELCADE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005064 ↗	PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 1	2000-02-01	Phase I trial to study the effectiveness of PS-341 in treating patients who have refractory or relapsed acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia in blast phase, or myelodysplastic syndrome. PS-341 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
NCT00006184 ↗	Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 2	2001-02-08	Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an incurable disease with a median survival of approximately 30 months. Allogeneic stem cell transplantation (SCT) results in a high percentage of complete remissions, but it can be associated with significant treatment-related mortality, which has been primarily attributed to conventional myeloablative transplant regimens. Recent clinical studies have shown that highly immunosuppressive yet non-myeloablative doses of fludarabine-based chemotherapy can result in alloengraftment. Even with a reduction in treatment related mortality, success with allogeneic SCT is limited by a significant risk of relapse. Donor immunization with myeloma Id in the setting of a non-myeloablative allogeneic SCT may represent a novel strategy for the treatment of multiple myeloma. Objectives: Primary Objectives: To induce cellular and humoral immunity in allogeneic stem cell donors and recipients against the unique idiotype expressed by the recipient's myeloma. To determine whether antigen-specific immunity, induced in the stem cell donor, can be passively transferred to the allogeneic SCT recipient in the setting of a non-myeloablative conditioning regimen. Secondary Objectives: To evaluate the effect of the Fludarabine-(etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide) EPOCH regimen on host T cell depletion and myeloid depletion prior to allogeneic SCT. To determine the efficacy of a novel conventional chemotherapy regimen (Fludarabine-EPOCH) in the setting multiple myeloma. To determine the treatment-related morbidity and mortality of allogeneic stem cell transplantation using a non-myeloablative conditioning regimen in multiple myeloma. To determine if the re-vaccination of allogeneic stem cell donors with the unique idiotype expressed by the recipient's myeloma will enhance cellular and humoral immunity to patient specific-idiotype prior to lymphocyte donation for the treatment of patients with recurrent or progressive disease after transplantation. Eligibility: Patients 18-75 years of age with Immunoglobulin G (IgG) or Immunoglobulin A (IgA) multiple myeloma. Patients must have achieved at least a partial remission following initial conventional chemotherapy regimen or after autologous stem cell transplantation. Consenting first degree relative matched at 6/6 or 5/6 human leukocyte antigen (HLA) antigens. Design: Phase 2 trial using a non-myeloablative conditioning regimen to reduce treatment-related toxicity. Recipient will undergo a plasmapheresis to obtain starting material for the isolation of idiotype protein. Donors would be immunized with an Id vaccine prepared from the patient. Prior to transplantation patients would receive a conventional chemotherapy regimen which contains agents active in myeloma and is T cell depleting. The allogeneic SCT would be performed with a conditioning regimen consisting of cyclophosphamide and fludarabine. The stem cell source would be blood mobilized with filgrastim. Recipients will be immunized with the Id vaccine following transplantation.
NCT00006773 ↗	Bortezomib in Treating Patients With Recurrent Glioma	Terminated	National Cancer Institute (NCI)	Phase 1	2001-05-01	Phase I trial to study the effectiveness of bortezomib in treating patients who have recurrent glioma. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
NCT00007878 ↗	Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery	Completed	National Cancer Institute (NCI)	Phase 1	2000-09-01	This phase I trial studies the side effects and best dose of bortezomib when given together with fluorouracil and leucovorin calcium in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fluorouracil and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with chemotherapy may be an effective treatment for solid tumors.

Clinical Trial Conditions for VELCADE

Condition Name

Condition Name for VELCADE
Intervention	Trials
Multiple Myeloma	219
Lymphoma	29
Mantle Cell Lymphoma	18
Unspecified Adult Solid Tumor, Protocol Specific	17

Condition MeSH

Condition MeSH for VELCADE
Intervention	Trials
Multiple Myeloma	290
Neoplasms, Plasma Cell	277
Lymphoma	114
Leukemia	55

Clinical Trial Locations for VELCADE

Trials by Country

Trials by Country for VELCADE
Location	Trials
Canada	105
Spain	79
Germany	73
France	71
Australia	50

Trials by US State

Trials by US State for VELCADE
Location	Trials
California	100
Texas	85
New York	84
Massachusetts	79
Florida	77

Clinical Trial Progress for VELCADE

Clinical Trial Phase

Clinical Trial Phase for VELCADE
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	1
Phase 4	13

Clinical Trial Status

Clinical Trial Status for VELCADE
Clinical Trial Phase	Trials
Completed	331
Terminated	107
Active, not recruiting	52

Clinical Trial Sponsors for VELCADE

Sponsor Name

Sponsor Name for VELCADE
Sponsor	Trials
National Cancer Institute (NCI)	151
Millennium Pharmaceuticals, Inc.	136
M.D. Anderson Cancer Center	26

Sponsor Type

Sponsor Type for VELCADE
Sponsor	Trials
Other	604
Industry	391
NIH	157

Last updated: July 27, 2026

VELCADE (bortezomib) market, clinical-trial updates, and patent-expiration outlook

Executive summary

• Drug: VELCADE (bortezomib), proteasome inhibitor for multiple myeloma and mantle cell lymphoma.
• Clinical development status: Post-approval activity is largely incremental (new schedules, combination regimens, and safety/real-world studies) rather than pivotal new Phase 3 programs that would materially reset the exclusivity clock.
• Market position: VELCADE remains established in treated multiple myeloma regimens, with demand shaped by adoption of newer agents (e.g., anti-CD38 antibodies, IMiDs, newer proteasome inhibitors) and line-of-therapy shifts.
• Exclusivity/patent exposure: Bortezomib is off primary biologic/small-molecule “newness” footing; competitive risk is dominated by formulation, dosing/schedule, and use patents, plus generic/biosimilar-style competition in jurisdictions with abbreviated pathways for copies.
• Commercial projection: Near-term revenue depends on (1) durability of use in standard regimens and (2) share pressure from newer proteasome inhibitors and combination-optimized standards. Total market growth is modest; substitution effects are the main driver.

---

VELCADE clinical trials update: what new studies are ongoing for bortezomib in multiple myeloma and mantle cell lymphoma?

Direct answer

• Current activity for VELCADE in public registries concentrates on combination regimens, real-world evidence, and protocol refinements (dose, schedule, supportive care) rather than brand-new mechanism claims.

Trials most commonly seen in registries for bortezomib

1. Relapsed/refractory multiple myeloma (RRMM) combinations

   • Bortezomib paired with IMiDs (e.g., lenalidomide) and/or corticosteroids.
   • Schedules tested to reduce peripheral neuropathy and improve tolerability.

2. Front-line and consolidation/maintenance studies

   • Trials evaluate bortezomib-containing induction in transplant-eligible and transplant-ineligible settings.
   • Maintenance-like strategies appear less frequently than with other drug classes, but schedule optimization is recurring.

3. Neuropathy risk mitigation protocols

   • Dose adjustments, treatment delays, and monitoring strategies are common endpoints.

4. Mantle cell lymphoma (MCL)

   • Smaller trial footprint than multiple myeloma.
   • Uses often test bortezomib-based combinations in relapsed disease.

What “update” usually means operationally

• Enrollment and completion rates tend to be concentrated in smaller interventional studies and non-interventional cohorts rather than large Phase 3 registrations.
• Any impactful study for commercial planning would be one that:
  • changes a labeled regimen or standard-of-care position, or
  • supports a new dosing schedule that improves safety and broadens eligible patient populations.
• Without a new pivotal label expansion, trial outcomes typically affect secondary uptake (site adoption, guideline influence) more than they reset regulatory exclusivity.

---

What is the current market for VELCADE (bortezomib) by indication and line of therapy?

Direct answer

• The market is dominated by multiple myeloma use in RR and selected newly diagnosed populations; mantle cell lymphoma is a smaller share.
• Share is pressured by newer proteasome inhibitors and antibody-based regimens, which increasingly anchor first-line and later-line pathways.

Indication mix (practical planning view)

• Multiple myeloma
  • Proteasome inhibition remains a core pharmacology class used in many treatment sequences.
  • VELCADE’s role varies by country guideline preferences and reimbursement.
• Mantle cell lymphoma
  • Use is more episodic and depends on local sequencing and clinician preference for proteasome inhibitor-containing regimens.

Line-of-therapy exposure

• VELCADE tends to be most active in:
  • earlier lines where proteasome inhibitors are still standard,
  • relapsed settings where combination availability and tolerability drive selection.

---

VELCADE market analysis: what factors drive demand growth or decline for bortezomib today?

Direct answer

• Demand is shaped by regimen substitution, tolerability perceptions, and payer/guideline preferences.

Growth headwinds

• Uptake shift toward newer regimens
  • Anti-CD38-based and newer proteasome inhibitor strategies change how clinicians sequence treatments.
• Toxicity management constraints
  • Peripheral neuropathy risk influences preference, dosing strategies, and discontinuation rates.
• Generic competition in multiple jurisdictions
  • Abbreviated entrants compress pricing unless protected by formulation or use patents.

Growth supports

• Durable clinician familiarity
  • Long real-world use yields experience with patient selection and supportive care pathways.
• Combination flexibility
  • Proteasome inhibitors integrate into many multi-agent schedules.

---

VELCADE revenue projection to 2028: what scenarios define upside and downside?

Direct answer

• Forecast range is primarily determined by share retention versus substitution by newer agents, and by pricing erosion from generic competition.
• Without a new pivotal label expansion, the base case typically tracks modest topline growth or decline driven by pricing offset with unit volume changes.

Scenario framework (planning-use)

Scenario	Key assumptions	Primary drivers
Base case	Modest volume durability; ongoing price compression	Generic penetration keeps eroding net price; regimen substitution offsets some units
Upside	Better neuropathy management adoption and stable reimbursement	Increased use in lines where bortezomib remains cost-effective and tolerated
Downside	Faster substitution to newer proteasome inhibitors and antibody-dominant regimens	Share shifts reduce units; deeper discounts accelerate margin compression

---

What patents protect VELCADE (bortezomib) in the US and key markets?

Direct answer

• Protection is concentrated in formulation, packaging/dosage design, method-of-use, and treatment schedule patents rather than broad composition-of-matter, given that bortezomib’s core invention has moved well past original basic patent life.

Patent estate categories to map for enforcement or licensing

1. Formulation and delivery
   • Stabilization, reconstitution behavior, and excipient systems.
2. Dosage/schedule
   • Dosing cadence changes and neuropathy-mitigation schedules can be protected.
3. Methods of use
   • Specific patient subsets, combination regimens, or line-of-therapy definitions.

Practical licensing implication

• If a generic enters via an abbreviated pathway, the litigation or licensing path usually targets:
  • specific claims tied to schedule and/or use, or
  • specific formulation claims for the branded presentation.

---

When does VELCADE lose exclusivity? What are the key expiration dates to watch?

Direct answer

• VELCADE’s commercial exclusivity is driven by:
  • patent expiration for schedule/use/formulation claims, and
  • any data exclusivity and market exclusivity periods that can vary by jurisdiction and approval history.
• For business planning, the risk window is the period when the last enforceable patent claim expires or is invalidated/settled, enabling generic labeling and market entry.

Expiration risk mapping (how to structure diligence)

• Identify the last-to-expire US patent(s) with:
  • Orange Book listings for bortezomib products, and
  • any later-introduced “minor” patents tied to formulation or method claims.
• Extend the same mapping across:
  • EU (national validation and SPC equivalents if applicable),
  • UK,
  • Canada,
  • select APAC jurisdictions based on market priority.

---

How many patents cover VELCADE on the Orange Book, and what are the claim types?

Direct answer

• The Orange Book patent list drives how many Orange Book-listed patents exist for the branded product(s); the business question is how many are:
  • formulation,
  • method-of-use,
  • and dosage/schedule.
• Without the exact Orange Book listing set in the prompt data, the count cannot be stated here.

---

What generic entry risks exist for VELCADE (bortezomib) products under US FDA pathways?

Direct answer

• The entry risk is highest where remaining patents are weak or narrow (schedule/use) and where generics can design around formulation claims.
• For US-specific risk modeling, the key signal is whether Paragraph IV certifications were filed against any remaining listed patents.

What to monitor in Paragraph IV filings

• Certification type against each Orange Book patent:
  • “Not valid,” “Not infringed,” “No longer manufacturing,” or “Expires on.”
• Litigation track record:
  • if disputes settled, what the agreed design-around or launch date implies.

---

VELCADE patent litigation: what cases affect generic launch timing?

Direct answer

• Litigation timing for bortezomib has historically been driven by disputes over:
  • method-of-use or formulation claims tied to schedule or patient selection,
  • and settlement terms that fix a launch date or restrict labeling.
• Without the prompt’s case list, this cannot be enumerated precisely here.

---

How does VELCADE compare with newer proteasome inhibitors (e.g., ixazomib, carfilzomib) in commercial trajectory?

Direct answer

• Clinician and payer preferences increasingly shift toward proteasome inhibitors with:
  • improved convenience (oral administration) or
  • different toxicity profiles that support broader patient eligibility.
• VELCADE competes through:
  • clinical familiarity and regimen integration,
  • and cost-effectiveness in settings where newer agents face access barriers.

Competitive substitution map

• Oral proteasome inhibitor strategies can reduce clinic infusion burden, shifting preference.
• Second-generation IV proteasome inhibitors can shift choice based on neuropathy tolerability and cardiopulmonary considerations.

---

VELCADE regulatory status: what is the current FDA label positioning for bortezomib?

Direct answer

• VELCADE remains an FDA-labeled proteasome inhibitor with indications that include multiple myeloma and mantle cell lymphoma, with dosing and schedule described on-label.
• Ongoing clinical evidence primarily supports schedule and combination use consistent with post-approval practice.

---

What formulations of VELCADE are commercially relevant, and what patent barriers can protect them?

Direct answer

• Patent barriers typically attach to:
  • how the drug is formulated and stabilized for reconstitution,
  • the labeled injection preparation,
  • and specific dose/schedule regimens that mitigate adverse events.

Formulation/IP diligence checklist

• Look for:
  • excipient composition patents,
  • reconstitution/stability patents,
  • and claims tied to dosing cycles.

---

Key takeaways

• VELCADE’s clinical updates are largely schedule- and combination-focused rather than label-resetting pivotal studies.
• Market demand is steady but structurally pressured by newer anti-myeloma regimen standards and pricing compression from generic competition.
• The competitive risk is less about the original bortezomib “composition” and more about formulation and method-of-use/schedule claims that can delay or constrain generic labeling and launch.
• Revenue projections depend on share retention vs substitution and net price erosion, not on blockbuster-like new indication expansion.

---

FAQs

1. What is the main clinical reason VELCADE dosing schedules are adjusted in multiple myeloma?
2. Which bortezomib-containing regimens most commonly appear in relapsed/refractory multiple myeloma?
3. Do bortezomib formulation patents typically cover excipient composition or reconstitution/stability behavior?
4. How do Paragraph IV certifications against Orange Book patents influence generic timing for bortezomib products?
5. How does bortezomib neuropathy risk management affect real-world continuation rates and dosing patterns?

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
2. ClinicalTrials.gov. bortezomib studies. (Accessed 2026).
3. National Cancer Institute. Bortezomib (VELCADE) and regimen summaries. (Accessed 2026).